ONC:NSD-BeiGene, Ltd. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 247.07

Change

0.00 (0.00)%

Market Cap

USD 28.70B

Volume

0.66M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 76.39B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
RPRX Royalty Pharma Plc

N/A

USD 18.65B
SMMT Summit Therapeutics PLC

N/A

USD 17.01B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B
INSM Insmed Inc

N/A

USD 13.70B

ETFs Containing ONC

S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.11B
UIMY:F UBS (Lux) Fund Solutions .. 2.18 % 0.00 %

N/A

USD 0.03B
EDGE:CA Evolve Innovation Index F.. 1.49 % 0.60 %

N/A

CAD 0.04B
ZLI:CA BMO Low Volatility Intern.. 0.00 % 0.42 %

N/A

CAD 0.23B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.11B
UD02:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.03B
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.11B
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 28.70B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector